Elsevier Bolsters Pharma Offerings With Windhover Buy


Global STM publisher Elsevier yesterday announced its acquisition of Windhover Information Inc. Windhover is a healthcare business intelligence company that provides analysis and commentary on healthcare business strategy, industry deal making, marketplace trends and medical start-ups. Terms of the deal were not disclosed.

Among Windhover's products are journals (including IN VIVO and the RPM Report), a database of healthcare industry transactions (Strategic Transactions Database), as well as a series of medical-device and biopharmaceutical partnering and strategy conferences.

Windhover will be integrated into Elsevier's pharma business intelligence unit, which also houses F-D-C Reports Inc. ("The Pink Sheet" and "The Gray Sheet") and the drug development database, Inteleos.

In a statement announcing the deal, Elsevier notes that the Windhover buy is in line with the company's e-health strategy to provide a strong combination of technology and content to its pharmaceutical professional customer base. Windhover is just one more investment Elsevier has made recently in content, workflow tools and e-health services, the statement also notes.

Elsevier really understands the importance of providing customers both the content and tools to accomplish their goals. This acquisition represents how knowledgeable Elsevier is about customer needs. Without tools and analysis, content's value is truly limited. Companies like Windhover can really help organizations like Elsevier provide even more value. Expect Elsevier to further bolster its content and tools capabilities with additional acquisitions.

Comment